TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
This Quarter Return
-5.03%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$1.81B
AUM Growth
+$1.81B
(+20%)
Cap. Flow
+$415M
Cap. Flow
% of AUM
22.93%
Top 10 Holdings %
Top 10 Hldgs %
39.2%
Holding
208
New
25
Increased
77
Reduced
32
Closed
6
Top Buys
| 1 |
Dynavax Technologies
DVAX
|
$50.6M |
| 2 |
Galapagos
GLPG
|
$45.2M |
| 3 |
Kiniksa Pharmaceuticals
KNSA
|
$33.1M |
| 4 |
Spyre Therapeutics
SYRE
|
$33.1M |
| 5 |
SLRN
ACELYRIN
SLRN
|
$24.3M |
Top Sells
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$10.6M |
| 2 |
OMIC
Singular Genomics Systems, Inc. Common Stock
OMIC
|
$7.23M |
| 3 |
GRAL
GRAIL, Inc. Common Stock
GRAL
|
$4.82M |
| 4 |
ALMS
Alumis Inc. Common Stock
ALMS
|
$4.72M |
| 5 |
Seer Inc
SEER
|
$1.52M |
Sector Composition
| 1 | Healthcare | 94.79% |
| 2 | Technology | 1.25% |
| 3 | Communication Services | 1.23% |
| 4 | Consumer Discretionary | 0.99% |
| 5 | Financials | 0.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Moderna
MRNA
$9.36B
| $8.66M | 0.48% |
305,300
+5,300
| +2% | +$150K |
|
52
Cullinan Oncology
CGEM
$456M
| $8.49M | 0.47% |
1,121,138
+200,000
| +22% | +$1.51M |
|
53
Elanco Animal Health
ELAN
$8.62B
| $8.4M | 0.46% |
800,100
+100
| +0% | +$1.05K |
|
54
Pliant Therapeutics
PLRX
$105M
| $8.1M | 0.45% |
+6,000,000
| New | +$8.1M |
|
55
Bausch + Lomb
BLCO
$5.18B
| $7.98M | 0.44% |
550,000
+100,000
| +22% | +$1.45M |
|
56
Insmed
INSM
$30.3B
| $7.63M | 0.42% |
100,000
| – | – |
|
57
Phathom Pharmaceuticals
PHAT
$843M
| $7.52M | 0.42% |
1,200,000
+700,000
| +140% | +$4.39M |
|
58
Apogee Therapeutics
APGE
$2.27B
| $7.47M | 0.41% |
200,000
+100,000
| +100% | +$3.74M |
|
59
HilleVax
HLVX
$105M
| $7.13M | 0.39% |
4,920,000
| – | – |
|
60
ImmunityBio
IBRX
$2.24B
| $7.02M | 0.39% |
2,333,333
-480,859
| -17% | -$1.45M |
|
61
Nuvation Bio
NUVB
$1.08B
| $6.86M | 0.38% |
3,900,000
| – | – |
|
62
ESSA Pharma
EPIX
$11.2M
| $6.79M | 0.38% |
4,300,000
| – | – |
|
63
Edgewise Therapeutics
EWTX
$1.54B
| $6.6M | 0.37% |
300,000
| – | – |
|
64
Viking Therapeutics
VKTX
$3.02B
| $6.52M | 0.36% |
270,000
-50,000
| -16% | -$1.21M |
|
65
Design Therapeutics
DSGN
$339M
| $6.49M | 0.36% |
1,680,975
+200,000
| +14% | +$772K |
|
66
Regeneron Pharmaceuticals
REGN
$59.8B
| $6.34M | 0.35% |
10,000
+8,000
| +400% | +$5.07M |
|
67
Adicet Bio
ACET
$60.8M
| $6.21M | 0.34% |
8,223,612
+77,624
| +1% | +$58.6K |
|
|
BIOA
68
BioAge Labs, Inc. Common Stock
BIOA
$170M
| $6.02M | 0.33% |
1,600,000
+281,639
| +21% | +$1.06M |
|
69
BioCryst Pharmaceuticals
BCRX
$1.74B
| $6M | 0.33% |
800,000
| – | – |
|
70
Iovance Biotherapeutics
IOVA
$800M
| $5.99M | 0.33% |
1,800,000
+1,300,000
| +260% | +$4.33M |
|
71
AbCellera Biologics
ABCL
$1.19B
| $5.8M | 0.32% |
2,600,000
+17,184
| +0.7% | +$38.3K |
|
72
Rocket Pharmaceuticals
RCKT
$358M
| $5.67M | 0.31% |
850,000
+100,000
| +13% | +$667K |
|
73
Heron Therapeutics
HRTX
$204M
| $4.92M | 0.27% |
2,235,459
+95,188
| +4% | +$209K |
|
74
Lantheus
LNTH
$3.75B
| $4.88M | 0.27% |
50,000
| – | – |
|
75
Dianthus Therapeutics
DNTH
$781M
| $4.8M | 0.27% |
264,692
| – | – |
|